Methadone Hydrochloride (Dolophine) Veterinary Grade API is supplied as the hydrochloride salt of the synthetic opioid methadone, CAS 1095-90-5, molecular formula C₂₁H₂₇NO·HCl, and relative molecular mass 345.91 g/mol. The veterinary-grade material is a white crystalline powder described in the USP monograph as freely soluble in water, soluble in alcohol, and practically insoluble in ether. It supports the manufacture of tablets, injections, capsules, powders, granules, premixes, and oral solutions where the finished veterinary medicinal product is registered by the relevant national authority. The product is a controlled substance in many jurisdictions; handling, reconciliation, storage, and distribution require compliance with national controlled-drug regulations and veterinary GMP requirements, including 21 CFR Part 210 and 21 CFR Part 211 in the United States or equivalent EU GMP Part II provisions. The API is not interchangeable with methadone free base, which has materially lower aqueous solubility and would require different formulation and dissolution controls. Unless otherwise specified, the veterinary grade is the racemic hydrochloride; levomethadone hydrochloride is a separate registered entity and must not be substituted without regulatory authorization.

Methadone Hydrochloride Veterinary API: Pharmacopeial Release Limits and Tiered Dosage-Form Constraints

The compendial release specification for methadone hydrochloride establishes an assay by HPLC of 98.0%–102.0% on the dried basis. The USP monograph assigns a melting range of 233–236°C by USP <741>, loss on drying not more than 0.5% by USP <731>, and residue on ignition not more than 0.1% by USP <281>. Identification requires infrared absorption and a chloride test. Residual solvents must satisfy USP <467> limits for the declared manufacturing solvent system. Elemental impurities are controlled under USP <232> and USP <233> with final acceptance criteria derived from the finished veterinary product permitted daily exposure. No single particle-size specification is mandated by the monograph; the manufacturer must establish D10, D50, and D90 control ranges by laser diffraction per USP <429> according to the intended dosage form. These compendial tests are considered minimum release criteria for solid oral, injectable, and premix applications; additional lot-specific limits are required for sterile injectable manufacture, including bacterial endotoxins and bioburden.

For tablets and capsules, the freely soluble hydrochloride salt can generate punch filming or capsule shell embrittlement if residual moisture and excipient water activity are not controlled. Production-scale direct compression of low-dose methadone hydrochloride veterinary tablets is generally limited by blend segregation and content uniformity rather than dissolution rate. Blend sampling should follow USP <905> stratified sampling principals, with acceptance value reporting on final tablets. An instrumented rotary tablet press is necessary because ejection force and compression force profiles provide early detection of over-lubrication or granule hardening. Published data for methadone-specific direct compression thresholds is limited; therefore, process validation must include a design of experiments across lubricant concentration, mixer rpm, and final blend hold time rather than reliance on single-point optimization.

What Limits Injectable Methadone Hydrochloride Solutions to Preservative-Screened Formulations and Endotoxin-Controlled Processing?

Injectable dosage forms are prepared as aqueous solutions of methadone hydrochloride, with pH adjusted to avoid free base precipitation above the pK_a. The limiting controls are not solubility but sterility assurance, endotoxin burden, container-closure compatibility, and degradation during terminal moist heat processing. If the finished product is sterilized by steam at 121°C for 15 min, the overkill cycle must be justified by stability-indicating assay of methadone and specified degradants. Where heat-labile formulations are used, sterile filtration through 0.22 µm polyvinylidene fluoride or polyethersulfone membranes is validated for bacterial retention per ASTM F838-20 and for filter compatibility. Bacterial endotoxin limits are calculated from the maximum intended veterinary dose using USP <85>, with the threshold pyrogenic dose for intravenous administration of 5 EU/kg, and validated by kinetic chromogenic LAL or recombinant factor C methods. Multidose injectable solutions require antimicrobial effectiveness testing per USP <51>, and preservative selection must be screened against the target species because benzyl alcohol and parabens show species-specific safety restrictions in cats and other small animals. Production suites handling injectable methadone hydrochloride should maintain controlled room temperature and low bioburden processing areas; pre-sterilization bioburden limits are established at not more than 10 CFU/100 mL as a common pre-filter action limit, but final limits must be derived from filter validation and process capability.

Veterinary premix, powder, and granule applications introduce different homogeneity and carryover issues. Because methadone hydrochloride is active at low mass fractions in in-feed premixes, the API is generally pre-blended by geometric dilution with a compatible carrier such as lactose monohydrate or microcrystalline cellulose. A double-ribbon blender or V-blender operated at 50%–70% nominal fill volume should be validated by sampling at multiple defined points followed by HPLC assay. Carryover of a controlled opioid API represents a serious cross-contamination risk; cleaning validation using swab and rinse sampling with acceptance limits derived from the health-based exposure limit is required. Dedicated equipment or verified campaign segregation is standard for controlled veterinary substances. Powder blends intended for capsules should be evaluated for flow function coefficient and particle-size segregation. If flow function coefficient falls below 4.0, force-feeder-assisted capsule filling or roller compaction is required to maintain weight uniformity. Granules for solution or suspension reconstitution are usually manufactured by wet granulation to improve dispersibility and dose uniformity, but addition rates of polymeric binders must be kept low enough to avoid delayed release in the target species.

When Methadone Hydrochloride Veterinary Granules Are Prepared by Fluid-Bed Top Spray Instead of High Shear Wet Massing

Fluid-bed top-spray granulation is selected when the finished veterinary product requires rapidly dispersible granules for oral solution or in-feed premix use. The aqueous binder solution is sprayed onto a fluidized bed of API and diluent at inlet air temperature typically between 50°C and 70°C, with product temperature monitored to avoid hydrate formation or surface pitting of the freely soluble hydrochloride salt. In contrast, high-shear wet massing in a jacketed granulator requires tighter endpoint control because the methadone hydrochloride dissolves partially in the granulating fluid and can redistribute during drying, leaving API-rich fines or surface crystals. Granulation endpoint should be determined by impeller power draw and torque, not by fixed time alone, because batch moisture variation shifts the end-point power curve. After drying, the granules are milled through a conical mill equipped with a round-hole screen, with screen size selected to achieve the registered D90. In-process moisture is controlled by loss-on-drying at ≤0.5% for capsules and tablets, while powder for oral solution may have a higher validated moisture limit if supported by stability data.

The distinction between veterinary-grade methadone hydrochloride and other opioid salts is principally physicochemical and regulatory rather than pharmacological identity. Compared with morphine hydrochloride, methadone hydrochloride is more lipophilic and demonstrates N-methyl-D-aspartate receptor antagonist activity in addition to μ-opioid agonist activity. Compared with fentanyl citrate, methadone hydrochloride is not typically supplied as a transdermal system, and its veterinary use requires species-specific pharmacokinetic characterization because elimination is highly variable in dogs, cats, and horses. The hydrochloride salt is preferred over the free base for aqueous injectable and oral solution manufacture due to its high water solubility, while capsule and tablet manufacturers must manage its solubility-driven moisture sensitivity. The API does not contain rate-controlling excipients or finished-dosage matrices; those are selected and validated by the veterinary marketing authorization holder. Published data for methadone hydrochloride in certain veterinary premix and granule configurations is limited, and formulation-specific stability and homogeneity studies are required before commercial batch release.